vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and EVOLUTION PETROLEUM CORP (EPM). Click either name above to swap in a different company.
EVOLUTION PETROLEUM CORP is the larger business by last-quarter revenue ($20.7M vs $18.7M, roughly 1.1× CytomX Therapeutics, Inc.). EVOLUTION PETROLEUM CORP runs the higher net margin — 5.2% vs -0.8%, a 6.0% gap on every dollar of revenue. On growth, EVOLUTION PETROLEUM CORP posted the faster year-over-year revenue change (2.0% vs -25.7%). Over the past eight quarters, EVOLUTION PETROLEUM CORP's revenue compounded faster (-5.2% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs EPM — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $20.7M |
| Net Profit | $-154.0K | $1.1M |
| Gross Margin | — | 44.3% |
| Operating Margin | -6.9% | 3.2% |
| Net Margin | -0.8% | 5.2% |
| Revenue YoY | -25.7% | 2.0% |
| Net Profit YoY | 97.6% | 158.4% |
| EPS (diluted) | — | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $20.7M | ||
| Q3 25 | — | $21.3M | ||
| Q2 25 | $18.7M | $21.1M | ||
| Q1 25 | $50.9M | $22.6M | ||
| Q4 24 | $38.1M | $20.3M | ||
| Q3 24 | $33.4M | $21.9M | ||
| Q2 24 | $25.1M | $21.2M | ||
| Q1 24 | $41.5M | $23.0M |
| Q4 25 | — | $1.1M | ||
| Q3 25 | — | $824.0K | ||
| Q2 25 | $-154.0K | $3.4M | ||
| Q1 25 | $23.5M | $-2.2M | ||
| Q4 24 | $18.9M | $-1.8M | ||
| Q3 24 | $5.7M | $2.1M | ||
| Q2 24 | $-6.5M | $1.2M | ||
| Q1 24 | $13.8M | $289.0K |
| Q4 25 | — | 44.3% | ||
| Q3 25 | — | 38.5% | ||
| Q2 25 | — | 46.1% | ||
| Q1 25 | — | 40.7% | ||
| Q4 24 | — | 36.9% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | 46.3% | ||
| Q1 24 | — | 45.2% |
| Q4 25 | — | 3.2% | ||
| Q3 25 | — | -0.4% | ||
| Q2 25 | -6.9% | 6.3% | ||
| Q1 25 | 44.4% | 7.0% | ||
| Q4 24 | 46.4% | -3.0% | ||
| Q3 24 | 12.3% | 8.5% | ||
| Q2 24 | -33.7% | 11.3% | ||
| Q1 24 | 28.1% | 9.1% |
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | -0.8% | 16.2% | ||
| Q1 25 | 46.2% | -9.7% | ||
| Q4 24 | 49.6% | -9.0% | ||
| Q3 24 | 17.2% | 9.4% | ||
| Q2 24 | -26.0% | 5.8% | ||
| Q1 24 | 33.3% | 1.3% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | — | $0.10 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $0.04 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $3.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $67.5M |
| Total Assets | $175.1M | $169.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $3.8M | ||
| Q3 25 | — | $714.0K | ||
| Q2 25 | $49.0M | $2.5M | ||
| Q1 25 | $47.6M | $5.6M | ||
| Q4 24 | $38.1M | $11.7M | ||
| Q3 24 | $40.6M | $6.9M | ||
| Q2 24 | $43.2M | $6.4M | ||
| Q1 24 | $36.2M | $3.1M |
| Q4 25 | — | $67.5M | ||
| Q3 25 | — | $69.1M | ||
| Q2 25 | $119.9M | $71.8M | ||
| Q1 25 | $25.0M | $71.7M | ||
| Q4 24 | $-456.0K | $76.3M | ||
| Q3 24 | $-23.5M | $79.6M | ||
| Q2 24 | $-31.2M | $81.1M | ||
| Q1 24 | $-31.7M | $83.5M |
| Q4 25 | — | $169.3M | ||
| Q3 25 | — | $169.1M | ||
| Q2 25 | $175.1M | $160.3M | ||
| Q1 25 | $98.5M | $156.4M | ||
| Q4 24 | $120.5M | $160.2M | ||
| Q3 24 | $139.0M | $157.9M | ||
| Q2 24 | $159.2M | $162.9M | ||
| Q1 24 | $184.7M | $166.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $5.4M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 5.09× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.4M | ||
| Q3 25 | — | $7.8M | ||
| Q2 25 | $-15.8M | $10.5M | ||
| Q1 25 | $-21.0M | $7.3M | ||
| Q4 24 | $-19.9M | $7.7M | ||
| Q3 24 | $-20.7M | $7.6M | ||
| Q2 24 | $-19.5M | $8.0M | ||
| Q1 24 | $-26.0M | $3.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | 5.09× | ||
| Q3 25 | — | 9.47× | ||
| Q2 25 | — | 3.06× | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 3.69× | ||
| Q2 24 | — | 6.47× | ||
| Q1 24 | -1.89× | 11.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
EPM
| Crude Oil | $10.7M | 52% |
| Natural Gas Reserves | $7.4M | 36% |
| Natural Gas Liquids Reserves | $2.5M | 12% |
